Disease progression among patients with metastatic lung, pancreatic, colorectal, and breast cancer is associated with statistically significant and clinically relevant reductions in health-related quality of life, real-world study data show.
The phase II SABR-COMET study has indicated that stereotactic ablative radiotherapy prolongs overall and progression-free survival versus palliative treatment in patients with up to five oligometastases.
Approximately one-fifth of patients with RAS and BRAF wild-type metastatic colorectal cancer derive clinical benefit from rechallenge with cetuximab plus irinotecan, Italian researchers report.
In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.
Patients whose colon cancers are detected by routine screening have fewer postoperative complications than individuals whose cancers are diagnosed outside of a national programme, study findings indicate.